Nava Therapeutics discloses it has raised $89M as it targets in vivo CAR-T and kidney delivery with novel lipid nanoparticles.
Nava Therapeutics, a secretive startup that’s been working on a new generation of lipid nanoparticles that target the bone marrow, immune cells and the kidney …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Financing supports the approval of U.S. Investigational Device Exemption (IDE), coronary clinical advancement, and expansion into…
The fresh funds will support the biotech's pipeline of RNA-based CAR-T cell therapies for cancer and autoimmune conditions.
City Therapeutics raises $99.5M Series B to advance three RNAi candidates into the clinic and expand its delivery platform beyond…
Boundless Bio hands Nasdaq listing to Serapha Bio in reverse merger with $230M in financing; CARsgen wins world's first CAR-T…
New York City-based startup Waypoint Bio has raised $20 million in series A financing to test multiple cell therapies in China.
CREATE Medicines has a new name, an expanded pipeline, and now fresh funding to propel the company’s first CAR-T candidates…
